Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Encephalitis ll: Pathophysiology

Encephalitis ll: Pathophysiology

Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...

Encephalitis l: Introduction

Encephalitis l: Introduction

Encephalitis is inflammation of the brain parenchyma, most often due to infections or autoimmune processes. It presents with neuropsychiatric features such as fever, altered mental status, behavioral changes, cognitive dysfunction, seizures, focal deficits, and sometimes autonomic instability. In some cases, the meninges are also involved, resulting in meningoencephalitis.Infectious CausesInfectious encephalitis is most commonly viral but can also result from bacterial, fungal, or parasitic...

Cerebral Edema ll: Pathophysiology

Cerebral Edema ll: Pathophysiology

Vasogenic edema is a major form of cerebral edema characterized by abnormal accumulation of fluid in the brain’s extracellular space due to disruption of the blood–brain barrier (BBB). The BBB is a specialized structure composed of endothelial cells connected by tight junctions, supported by astrocytic endfeet and a basement membrane. Under normal conditions, it tightly regulates the movement of ions, proteins, and solutes between the bloodstream and brain parenchyma. When this...

Hepatic Encephalopathy

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic...

Multiple Sclerosis l: Introduction

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

Alzheimer Disease ll: Pathophysiology

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Correction: Performance of the national institute of infectious diseases disability scale in HTLV-1-associated myelopathy/tropical spastic paraparesis.

Journal of neurovirology·2023

Same author

Performance of the National Institute of Infectious Diseases disability scale in HTLV-1-associated myelopathy/tropical spastic paraparesis.

Journal of neurovirology·2023

Same author

Meningeal Sporotrichosis Due to <i>Sporothrix brasiliensis</i>: A 21-Year Cohort Study from a Brazilian Reference Center.

Journal of fungi (Basel, Switzerland)·2023

Same author

<i>Sporothrix brasiliensis</i> meningitis in an immunocompetent patient.

Practical neurology·2021

Same author

Isolated intracranial hypertension associated with COVID-19.

Cephalalgia : an international journal of headache·2020

Same author

Peripheral facial nerve palsy associated with COVID-19.

Journal of neurovirology·2020

Search research articles

Related Experiment Video

Updated: May 6, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Progressive multifocal leukoencephalopathy: new concepts.

Arquivos De Neuro-Psiquiatria

|October 22, 2013

Summary

This summary is machine-generated.

Progressive multifocal leukoencephalopathy (PML), a CNS demyelinating disease caused by JC virus (JCV), is evolving. New immunomodulatory drugs have altered its epidemiology, presentation, and prognosis, necessitating updated understanding and treatment strategies.

More Related Videos

Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo

Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo

Published on: March 26, 2019

Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis

Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis

Published on: February 23, 2024

Related Experiment Videos

Last Updated: May 6, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo

Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo

Published on: March 26, 2019

Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis

Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis

Published on: February 23, 2024

Area of Science:

Neuroimmunology
Infectious Diseases
Neurology

Background:

Progressive multifocal leukoencephalopathy (PML) is a rare, severe demyelinating disease of the central nervous system (CNS).
PML is caused by the reactivation of JC virus (JCV) in immunosuppressed individuals, historically seen in advanced HIV/AIDS, lymphoproliferative disorders, and transplant recipients.
Recent shifts in PML epidemiology are linked to the widespread use of HIV antiretroviral therapies and novel immunomodulatory/immunosuppressive medications like Rituximab and Natalizumab.

Purpose of the Study:

To discuss emerging concepts in Progressive multifocal leukoencephalopathy (PML).
To highlight recent modifications in PML epidemiology and clinical presentation.
To review the impact of new immunomodulatory treatments on PML, including PML-IRIS, and explore novel therapeutic strategies.

Main Methods:

Review of current literature and epidemiological data on PML.
Analysis of the impact of specific immunomodulatory and immunosuppressive drugs on PML.
Discussion of clinical management and emerging treatment strategies for PML and JCV-related CNS diseases.

Main Results:

The epidemiology, clinical features, and prognosis of PML have been significantly altered by modern medical treatments.
Newer immunosuppressive and immunomodulatory therapies are associated with changes in PML incidence and presentation.
Immune reconstitution inflammatory syndrome (IRIS) is a critical consideration in PML management, particularly with treatment initiation or modification.

Conclusions:

Understanding the evolving landscape of PML is crucial for timely diagnosis and effective management.
The advent of targeted immunotherapies necessitates a re-evaluation of PML risk, surveillance, and treatment protocols.
Further research into JCV pathogenesis and novel therapeutic interventions is required to improve outcomes for patients with PML and related CNS disorders.